Advertisement

Related Videos

Daniel Goldstein, MD: Interventional Pharmacoeconomics - Why and How

Javid J. Moslehi, MD, on Cardiovascular and Thrombotic Considerations of Kinase Inhibitors: The Case of BTK Inhibitors

Boon-Cher Goh, MD, on Cancer Drugs in Singapore: 3As (Availability, Accessibility, and Affordability)

Mark Sculpher, PhD: How Do We Assess the Value of Cancer Drug Optimization?

Opportunities to Optimize Cancer Policies Panel Discussion

Advertisement

Advertisement




Sep
01
Today In Oncology
Biomarker Guides Treatment Sequencing Predicts Outcomes in BRAF-Mutated Metastatic Melanoma
High-Dose Vitamin D3 Does Not Improve PFS in Metastatic Colorectal Cancer
Additional Safety Analysis of DESTINY-Breast05: What Did It Show?
FDA Approves Ropeginterferon Alfa-2b-njft for Essential Thrombocythemia
FDA Approves Rusfertide for Erythrocytosis in Adults With Polycythemia Vera
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo